Epidemiology and comorbidity of juvenile idiopathic arthritis in Poland– a nationwide study
Authors' conclusion
Our findings indicate that both the occurrence of new cases and overall burden of JIA in the past ten years align with the lower end of projected figures for our geographical area, especially when compared with Scandinavian nations.
Study context
- Population
- Individuals aged < 16 years with juvenile idiopathic arthritis (JIA) in Poland, National Health Fund records 2010–202229,758 prevalent JIA cases in 2022
- Outcome
- Incidence and prevalence of JIA
- Follow-up
- 2022
Methodological detailsNational Health Fund (NHF) healthcare utilization records 2010–2022, narrow JIA case definition: repeat ICD-10 encoding plus DMARD prescription (ATC codes)
- NHF healthcare utilization records 2010–2022
- Narrow JIA case definition: repeat ICD-10 encoding plus DMARD prescription (ATC codes)
Main finding
As reported in the abstract
Incident JIA cases
1,625
Prevalent JIA cases
29,758
Incidence rate per 100,000 persons of the general population
4.30
Prevalence rate per 100,000 persons of the general population
78.80
Observational data: associations, not effects.
Further findings
Annual JIA IRs (< 16 years) in the pediatric population, per 100,000
- Lowest annual IR
- 24.0 (95% CI 22.8, 25.2)
- Highest annual IR
- 38.7 (95% CI 37.2-40.3)
Female vs male annual IR ratio
- Annual IR ratio range (greater susceptibility among females, consistently observed)
- 1.16 and 1.53
Most common concurrent disorders
- Allergic rhinitis
- N = 5,200, 17.5%
- Bronchial asthma
- N = 3,661, 12.3%
- Chronic tonsillitis/pharyngitis
- N = 3641, 12.2%
Annual healthcare cost per JIA patient (214,285 outpatient visits)
- Median annual cost (IQR; range)
- 37.8€ (35.8-47.4€, 30.3-86.1€)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →